SSII

SSII is a genuine hyper-growth story with a real product. Revenue more than doubled to $42.5M (+105.7%) on its SSi Mantra surgical robot, gross margin expanded to 46.0% (gross profit +131.2%), and the net loss narrowed to -$12.1M from -$19.2M as operating loss shrank to -$8.19M. Stockholders' equity jumped +184% to $38.2M and the current ratio is healthy (current assets $48.8M vs current liabilities $26.2M, liabilities/equity just 0.94x). India-based manufacturing (75,000 sq ft in Gurugram) gives a structural cost edge that MD&A explicitly credits for affordability — a durable moat in an underpenetrated market. On trajectory alone this looks like a buy.

But the balance sheet is fragile in exactly the wrong place. Operating cash flow was -$18.5M against just $3.21M of unrestricted cash (plus $6.4M restricted as bank security, not freely usable). Management states outright that the statements assume going concern and that 'these conditions raise substantial doubt about our ability to continue as a going concern,' and that in 2026 it 'plans to raise additional capital through further private or public offerings.' With ~194M shares already out and a -$55.8M accumulated deficit, that near-certain raise means dilution — and if markets tighten, MD&A warns it would have to 'limit expansion, R&D and marketing.' The reported net loss also flatters underlying operations: a $3.97M income-tax expense and $8.1M of stock comp muddy the picture.